April 12 (Reuters) - Rigel Pharmaceuticals Inc:
* FDA IS CONTINUING ITS REVIEW OF NDA AND PDUFA ACTION DATE FOR FOSTAMATINIB NDA IS APRIL 17
* DUE TO AN ERROR, INACCURATE INFORMATION WAS DISPLAYED REGARDING U.S. FDA'S REVIEW OF NDA FOR FOSTAMATINIB
* CO'S WEBSITE HAS BEEN CORRECTED Source text for Eikon: Further company coverage: